Introduction
============

Haploid cells are amenable for genetic analyses because they contain only one set of chromosomes. For example, the budding yeast *Saccharomyces cerevisiae* has been largely utilized as a model organism to understand important biological processes^[@bib1]^. Recently, mouse haploid embryonic stem cells (haESCs) have been successfully derived from parthenogenetic (PG)^[@bib2],[@bib3]^ and androgenetic (AG)^[@bib4],[@bib5]^ blastocysts, and applied to forward or reverse genetic screening^[@bib2],[@bib3]^ and production of genetically modified mice^[@bib4],[@bib5]^, showing a great potential in genetic studies in mammalian organisms^[@bib6]^. The success in mouse raises a particular challenging question of whether haESCs can be established in non-human primates. Owing to the dramatic genetic and physiologic similarities to human^[@bib7]^, non-human primates^[@bib8]^ represent the most ideal experimental models for basic and applied biomedical research. Normal diploid embryonic stem cell (ESC) lines have been generated from different types of non-human primate embryos, including rhesus^[@bib9]^, marmoset^[@bib10]^ and cynomolgus (*Macaca fascicularis*)^[@bib11]^ monkeys. However, different from murine, but similar to human ESCs, non-human primate ESCs proliferate at a low rate and need to be manually dissociated into small clumps for propagation^[@bib12],[@bib13]^. This property of non-human primate ESCs may hinder the derivation of haESCs, as the establishment of mouse haESCs is based on the haploid cell enrichment using single-cell-sorting technology^[@bib3],[@bib5]^.

In this study, we have established protocols for the derivation of haESCs from *Macaca fascicularis* monkey PG blastocysts. These cells display pluripotency *in vitro* and *in vivo*. Interestingly, the haploidy can be well maintained in MPH1 for more than 140 days without FACS enrichment of haploid cells. More importantly, we provide the evidence that monkey PG-haESCs can be genetically manipulated readily.

Results
=======

Derivation of haESC lines from monkey PG blastocysts
----------------------------------------------------

To generate PG haploid embryos from monkey, we adopted an artificial activation protocol, which was originally developed by Mitalipov *et al*.^[@bib14]^. Briefly, cumulus-free mature metaphase II (MII) oocytes from *Macaca fascicularis* monkey were treated sequentially with ionomycin, followed by cycloheximide (CHX). Ten hours after the activation, the second polar body and one female pronucleus could be observed ([Figure 1A](#fig1){ref-type="fig"}). Among 181 activated oocytes, 167 (92%) divided and 70 (39%) developed into blastocysts *in vitro* ([Table 1](#tbl1){ref-type="table"} and [Figure 1A](#fig1){ref-type="fig"}), similar to the developmental efficiency of intracytoplasmic sperm injection (ICSI) embryos ([Table 1](#tbl1){ref-type="table"}). All blastocysts derived from activated oocytes and ICSI controls were used for ESC derivation. After removal of zona pellucida, inner cell mass (ICM) was isolated via immunosurgery^[@bib15]^, plated on mitotically inactivated human fibroblast feeder (HFF)^[@bib16]^ feeder layers and cultured in a standard monkey ESC culture system^[@bib15],[@bib17]^, with the addition of ROCK inhibitors, 1 μM Thiazovivin and 10 μM Y-27632^[@bib18],[@bib19]^. ICM outgrowths were individually manually dissociated into small clumps and replated on new HFF feeder layers. The resulting colonies were further expanded by mechanical dissociation for several passages and then enzymatically dispersed, as described for human ESC derivation and passaging^[@bib18],[@bib20],[@bib21]^. Four diploid ESC lines were established from ICSI-derived blastocysts (referred to as MES1-MES4) ([Table 1](#tbl1){ref-type="table"}). Among 10 ESC lines that we established from PG blastocysts, two lines (referred to as MPH1 and MPH2), originated from two individual monkeys (183 and 118) ([Table 1](#tbl1){ref-type="table"}), contained haploid cells in the initial cell sorting. Strikingly, compared with the low ratio of haploid cells (\< 5%) at the first sorting during mouse AG-haESC derivation^[@bib5]^, the percentage of haploid cells in both MPH1 and MPH2 ([Figure 1B](#fig1){ref-type="fig"} and [Supplementary information, Figure S1A](#sup1){ref-type="supplementary-material"}) was substantially higher (about 30%). The haploidy of monkey PG-haESCs could be well maintained with regular FACS ([Figure 1B](#fig1){ref-type="fig"} and [Supplementary information, Figure S1A](#sup1){ref-type="supplementary-material"}) for over 30 passages. Karyotyping of these PG-haESCs revealed that both of the cell lines had a haploid set of 21 chromosomes ([Figure 1C](#fig1){ref-type="fig"} and [Supplementary information, Figure S1B](#sup1){ref-type="supplementary-material"}). Comparative genomic hybridization (CGH) of monkey PG-haESC lines confirmed that the haploid cells sustained genome integrity ([Figure 1D](#fig1){ref-type="fig"}, [Supplementary information, Figure S1C](#sup1){ref-type="supplementary-material"} and [Table S1](#sup1){ref-type="supplementary-material"}).

Pluripotency of monkey PG-haESCs
--------------------------------

Monkey PG-haESCs showed the colony morphology similar to that of normal ICSI-derived diploid ESCs. Immunostaining analyses detected the expression of typical monkey ESC markers, including *NANOG*, *OCT4*, *SSEA4*, *TRA-1-60* and *TRA-1-81* in PG-haESC colonies ([Figure 2A](#fig2){ref-type="fig"}) and diploid ESCs ([Supplementary information, Figure S2A](#sup1){ref-type="supplementary-material"}). Next, we compared the gene expression profiles of PG-haESCs with those of normal ESCs and monkey fibroblasts (MFs) from female individuals. Clustering of these cells based on microarray expression results showed a high correlation between PG-haESCs and control diploid ESCs, but not MFs ([Figure 2B](#fig2){ref-type="fig"} and [Supplementary information, Figure S3A](#sup1){ref-type="supplementary-material"}). To characterize the differentiation potential of monkey PG-haESCs and ICSI-derived ESCs, we suspended ESCs for the formation of embryoid body (EB) *in vitro*. We observed that PG-haESCs, similar to ICSI control ESCs ([Supplementary information, Figure S2B](#sup1){ref-type="supplementary-material"}), could differentiate into various cell types originating from all three embryonic germ layers, as demonstrated by the expression of *TUJ1*, *MAP2* (ectoderm markers), *ACTININ*, *VIMENTIN* (mesoderm markers), *SOX17*, *GATA6* and *FOXA2* (endoderm markers) ([Figure 2C](#fig2){ref-type="fig"} and [Supplementary information, Figure S3B](#sup1){ref-type="supplementary-material"}). To test the differentiation potential of PG-haESCs *in vivo*, we injected undifferentiated PG-haESCs and ICSI control ESCs into NOD SCID mice for teratoma formation. The formation of teratoma is considered as the most stringent standard of pluripotency for monkey ESCs^[@bib13]^ to date, as the recent report showed that monkey ESCs failed to support the generation of chimeras^[@bib22]^. Two or three months after injection, well-shaped teratomas were observed from both haploid and diploid ESCs. Histochemical analyses indicated the existence of a variety of tissues from all three embryonic germ layers, such as neural epithelium, pigment cells (ectoderm), cartilage, muscle (mesoderm), intestinal and respiratory epithelium (endoderm) ([Figure 2D](#fig2){ref-type="fig"}, [Supplementary information, Figures S2C](#sup1){ref-type="supplementary-material"} and [S3C](#sup1){ref-type="supplementary-material"}) in the teratomas, validating the pluripotency of monkey PG-haESCs.

Cellular origin of monkey PG-haESCs
-----------------------------------

As the haploid genome of MPH1 and MPH2 PG-haESC lines was from activated oocytes containing only one copy of genome, all chromosomes might be expected to display 100% of homozygosity in diploidized daughter cells. To test this hypothesis, we conducted short tandem repeat (STR) genotype and single-nucleotide polymorphism (SNP) analyses^[@bib23]^ using genomic DNA extracted from PG-haESCs and oocyte donor monkeys. The analysis of 24 STR loci confirmed that MPH1 originated from the egg donor 183, and MPH2 was from egg donor 118 ([Figure 3A](#fig3){ref-type="fig"} and [Supplementary information, Table S2](#sup1){ref-type="supplementary-material"}). As expected, both MPH1 and MPH2 cells exhibited homozygosity at all tested loci ([Supplementary information, Table S2](#sup1){ref-type="supplementary-material"}). Consistently, all 23 detected SNPs in PG-haESC lines were precisely inherited from the corresponding egg donors. Moreover, both cell lines displayed homozygosity for all tested SNPs ([Supplementary information, Figure S3B](#sup1){ref-type="supplementary-material"} and [Table S3](#sup1){ref-type="supplementary-material"}).

As genomic materials of PG-haESC lines originated from mature oocytes, in which maternal imprints were established during oogenesis, we anticipated that PG-haESCs might maintain maternal imprints. We first analyzed the expression of maternal and paternal imprinted genes in PG-haESCs and diploid ESCs from microarray results. As expected, mRNA levels of all detected paternally imprinted genes (expressed from the paternal allele) were lower in PG-haESCs than in diploid ESCs ([Supplementary information, Table S4](#sup1){ref-type="supplementary-material"}). In contrast, transcripts from most paternally imprinted genes (expressed from the maternal allele) in PG-haESCs had similar levels to those in diploid ICSI-derived ESCs ([Supplementary information, Table S4](#sup1){ref-type="supplementary-material"}). Quantitative RT-PCR results verified the different expression patterns of maternally and paternally imprinted genes in PG-haESCs ([Figure 3C](#fig3){ref-type="fig"}). Interestingly, a similar expression pattern was observed in monkey PG diploid ESCs^[@bib23]^. To further assess epigenetic inheritance, we performed bisulfite sequencing to analyze the methylation profiles of one maternally imprinted gene, *SNRPN*, and one paternally imprinted gene, *H19*. Consistent with the extremely low methylation level of *SNRPN* in sperm, the differentially methylated region (DMR) of *SNRPN* largely retained methylation in MPH1 and MPH2 ([Figure 3D](#fig3){ref-type="fig"}). In contrast, *H19*, which is normally unmethylated on the maternal allele, was partially methylated in both PG-haESC lines ([Figure 3D](#fig3){ref-type="fig"}). These results are consistent with the observations of epigenetic instability in monkey^[@bib9],[@bib24]^, human^[@bib25],[@bib26],[@bib27]^ and mouse^[@bib28],[@bib29]^ ESCs, particularly at the *H19* locus^[@bib5]^. Taken together, these data support the idea that monkey PG-haESCs are derived from parthenogenetically activated oocytes.

Haploidy in monkey PG-haESCs
----------------------------

MPH1 and MPH2 were derived from two independent PG blastocysts developed from two oocytes harvested from two individual donor monkeys (no. 183 and no. 118). The haploidy could be well maintained in both cell lines by regular FACS, and PG-haESCs were propagated without any signs of proliferative crisis. Interestingly, MPH1 and MPH2 showed distinct features regarding the maintenance of haploidy. We observed the high ratio of haploid cells (around 30%) in first cell sorting during the process of MPH1 and MPH2 formation ([Figure 1B](#fig1){ref-type="fig"} and [Supplementary information, Figure S1A](#sup1){ref-type="supplementary-material"}). We hypothesized that the haploidy could be stably maintained in MPH1 and MPH2 lines. To test this hypothesis, some cells were used for haploid cell enrichment in the first FACS, whereas others were directly replated without cell sorting and the haploidy was traced to determine when haploid cells would completely convert into the diploid state. Strikingly, haploid cells persisted for almost 140 days without sorting enrichment in MPH1 from the day when the ICM was plated on HFF feeder layers for ESC formation ([Figure 4A](#fig4){ref-type="fig"} and data not shown). After the second FACS enrichment for haploid cells, the haploid cells from MPH1 (MPH1^a^) were replated on HFF feeder layers and the haploidy could also be maintained for more than 100 days *in vitro* ([Figure 4A](#fig4){ref-type="fig"}). In contrast, the MPH2 line showed less stability in the haploidy maintenance compared with the MPH1 line. Without any cell sorting, haploid cells disappeared in MPH2 on day 58 after ICM was plated for ESC derivation. Consistently, enriched haploid cells from MPH2 (MPH2^a^) completely converted into the diploid state after 50 days in culture.

We then addressed whether the cell growth rate accounted for the different haploidy stability between MPH1 and MPH2 lines. To this end, we performed MTT assay, which is widely used to determine the cell growth rate^[@bib30],[@bib31]^. As shown in [Figure 4B](#fig4){ref-type="fig"}, the cells from MPH1 and MPH2 lines displayed a comparable growth rate. Furthermore, the growth rate of both MPH1 and MPH2 was similar to that of monkey diploid ESCs (MES1 and MES2, [Figure 4B](#fig4){ref-type="fig"}). Therefore, the distinct haploidy feature of MPH1 and MPH2 is not dependent on the cell growth rate, implying the possible existence of some essential differences between two individual donor monkeys that contributed to the difference in the haploidy maintenance between these two cell lines.

Mouse haploid ESCs quickly convert to diploid cells during development and differentiation^[@bib5]^. We next investigated whether monkey haploid cells could persist in teratomas derived from PG-haESCs. In two tested teratomas, haploid cells could not be detected ([Figure 4C](#fig4){ref-type="fig"}). Quantitative RT-PCR analyses showed that marker genes of various cell types from three embryonic germ layers, such as *BRACHURY* (mesoderm), *SOX17*, *FOXA2*, *FOXA1* (endoderm), *MAP2* and *PAX6* (ectoderm) were highly expressed in these diploid cells ([Figure 4D](#fig4){ref-type="fig"}). Thus, monkey haploid ESCs spontaneously converted into diploid cells during differentiation. Taken together, the haploidy maintenance in monkey PG-haESCs, similar to that in mouse haESCs^[@bib3],[@bib4],[@bib5],[@bib22]^, relies heavily on repeated cell sorting.

Genetic manipulation in monkey PG-haESCs
----------------------------------------

We next examined the feasibility of genetic manipulation in monkey PG-haESCs. We initially applied three different strategies to establish transgenic PG-haESCs. First, 5 × 10^5^ monkey PG-haESCs were infected with FUGW-lentivirus vectors carrying green-fluorescent protein (GFP)^[@bib33]^. Seven days after infection, FACS analysis showed that about 29% of cells were GFP-positive, in which 15% were haploid ([Supplementary information, Figure S4A](#sup1){ref-type="supplementary-material"}). Infected cells were replated on fresh feeder cells and GFP positive ESC colonies were observed ([Supplementary information, Figure S4A](#sup1){ref-type="supplementary-material"}). Second, we employed the transposon system, which has been applied for a variety of genetic manipulation in mouse^[@bib34],[@bib35]^ and human^[@bib36]^ cells, for producing transgenic monkey PG-haESCs. Donor *PB (Act-RFP)* element and the helper plasmid *ACT-PBase*^[@bib34]^ were co-transfected into PG-haESCs by lipofectamine. FACS analysis showed that about 29% of cells carried RFP transgene, in which 20% were haploid ([Supplementary information, Figure S4B](#sup1){ref-type="supplementary-material"}). We replated RFP-positive haploid cells and observed RFP-positive colonies after culturing for one week ([Supplementary information, Figure S4B](#sup1){ref-type="supplementary-material"}). Third, we tested the feasibility of drug selection in the derivation of monkey transgenic haploid cells. To this end, donor *PB (Act-RFP)* carrying a neomycin-resistant gene (*neo^r^*) and the helper plasmid *ACT-PBase* were co-transfected into PG-haESCs by lipofectamine. As expected, after 10 days of antibiotic (G418) selection, 84% of neomycin-resistant cells were RFP positive. FACS analysis indicated that almost all survived haploid cells were RFP positive ([Figure 5A](#fig5){ref-type="fig"}, left). G418-resistant cells were replated and RFP-positive colonies were randomly picked for expansion, leading to 12 transgenic haploid ESC lines ([Figure 5A](#fig5){ref-type="fig"}, right).

Efficient generation of transgenic monkey PG-haESC lines promoted us to explore the possibility of using monkey PG-haESCs for genome-wide genetic screenings ([Figure 5B](#fig5){ref-type="fig"}). To this end, we applied insertional mutagenesis by introducing both *PB (PGK-neo)* and *ACT-PBase* into PG-haESCs. After G418 selection, survived clones were individually picked and replated for expansion. FACS analysis confirmed that 18 out of 40 clones, derived from two independent experiments, contained haploid cells ([Figure 5C](#fig5){ref-type="fig"}), indicating that these clones originated from single neomycin-resistant haploid cell. Inverse PCR analyses revealed that 16 clones contained PB transposon integration sites ([Supplementary information, Figure S5A](#sup1){ref-type="supplementary-material"}) at an efficiency similar to PB insertion in human ESCs^[@bib37]^. DNA sequencing of PCR products showed that three genes (*PRKD1*, *NIF3L1* and *LIPC*) were mutated in four clones ([Supplementary information, Figure S5B](#sup1){ref-type="supplementary-material"}), respectively. Further genotyping analyses demonstrated that these clones contained only the mutated allele, whereas the control cells harbor only the wild-type allele ([Figure 5D](#fig5){ref-type="fig"}), supporting early observations that the mutagenesis occurred in haploid cells. As *LIPC* and *PRKD1* were not expressed in monkey ESCs ([Supplementary information, Figure S5C](#sup1){ref-type="supplementary-material"}), we then examined the expression of *NIF3L1*^[@bib38]^ in established mutated PG-haESC lines. As expected, the disruption of *NIF3L1* by PB resulted in extremely low levels of *NIF3L1* mRNA in both clones 206 and 224 ([Figure 5E](#fig5){ref-type="fig"}) compared with that in the wild-type haploid ESCs. These data provide the evidence that monkey PG-haESCs can be used for mutagenesis screening and for creating homozygous mutations.

Discussion
==========

Near-haploid cell lines have been established from human tumors^[@bib39],[@bib40]^ and applied to genetic screenings for host genes required for the action of toxins or viruses^[@bib41],[@bib42],[@bib43]^. However, the aneuploidy and cancerous characters of these cells have limited applications^[@bib6]^ in both basic and applied research. Here, we established two haploid ESC lines from monkey PG blastocysts, indicating the feasibility of generation of normal haploid cell lines from primates. Our PG-haESCs carry 21 chromosomes and largely sustain genomic integrity. These cells express typical diploid markers of monkey diploid ESCs and can differentiate into various cell types of all three embryonic germ layers *in vitro* and *in vivo*. Importantly, genetic manipulation is feasible in these PG-haESCs.

Monkey ESC colonies are usually propagated by manual dissociation to small cell clusters^[@bib13],[@bib44]^ rather than single cells, as enzymatic treatment results in dramatic decrease in plating efficiency (\< 1%)^[@bib13]^. However, to enrich haploid cells, monkey PG-haESCs should be disaggregated into single cells for FACS. To solve this problem, we applied a modified single-cell enzymatic dissociation method employed in human ESC expansion^[@bib20],[@bib21],[@bib45],[@bib46]^, in which Accutase, instead of collagenase IV, was chosen for cell dissociation. Accutase is a formulated mixture of digestive enzymes, which can gently dissociate sensitive cells, such as human ESCs^[@bib19],[@bib47]^. Meanwhile, ROCK inhibitors, Thiazovivin and Y-27632, which have been recently used in human ESC derivation^[@bib18]^ and single-cell expansion^[@bib19]^, were also employed in our PG-haESC-derivation procedure. Presumably due to the use of these new methods, PG-haESCs derived from monkey oocytes can now be expanded for over 30 passages.

Interestingly, two monkey haploid ESC lines established in this study showed different capability in maintaining the haploidy. Consistently, their subclones (MPH1^a^ and MPHH2^a^, [Figure 4A](#fig4){ref-type="fig"}), which were from the first FACS-enriched haploid cells, exhibited a similar diploidization tendency to their originators. We have ruled out the possibility that cell growth rate accounts for the difference, as MPH1 and MPH2 displayed a similar cell growth rate ([Figure 4B](#fig4){ref-type="fig"}). Meanwhile, the cell growth rates of monkey haploid ESCs were not significantly different from that of monkey diploid ESCs, implying that this distinction is not related with ploidy of the cells. As MPH1 and MPH2 were generated from two individual donor monkeys, it is likely that the genetic background of these two monkeys may account for the difference. At present, we cannot exclude the possibility that the stability of haploidy in MPH1 is a chance event. More monkey haploid ESC lines need to be established in the future to address this issue. Nevertheless, further investigation into the underlying differences between MPH1 and MPH2, and differences between their donor monkeys may not only aid in our understanding of the haploidy maintenance, but also yield clues for improving the maintenance of haploid cells *in vitro*, allowing more efficient genome-wide screenings.

Most importantly, our PG-haESCs could be randomly mutated, and all mutations analyzed so far were homozygous, indicating that monkey haploid ESCs can be utilized for whole-genome screenings for elucidating the mechanisms involved in different biological processes. One intriguing application is to use our PG-haESCs for screening the key factors that may be employed for generation of naive human or non-human primate ESCs.

In summary, we have demonstrated that haploid ESCs can be generated from non-human primates and used as a tool for genetic screening. The next challenge is to establish haploid ESCs from non-human primate AG blastocysts, which can be used as a genetically tractable fertilization agent, like mouse AG-haESCs^[@bib4],[@bib5]^, for generating genetically modified monkey via injection into oocyte.

Materials and Methods
=====================

Animal use and care
-------------------

All animal procedures were performed under the ethical guidelines of the Institute of Biochemistry and Cell Biology, and the Institute of Neurosciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.

Parthenogenetic activation
--------------------------

Cumulus-free MII oocytes, 35-36 h post-hCG injection, were activated by exposure to 5 mM ionomycin for 5 min in TALP/HEPES medium supplemented with 1 mg/ml fatty acid-free BSA and then cultured in HECM-9 medium containing 7.5 μg/ml CHX at 37 °C in 6% CO~2~ for 5 h^[@bib14]^. Activated oocytes were transferred to four-well dishes containing protein-free HECM-9 medium covered with paraffin oil and cultured at 37 °C in 6% CO~2~, 5% O~2~ and 89% N~2~. Embryos that reached the eight-cell stage were transferred to four-well dishes with fresh HECM-9 medium supplemented with 5% fetal bovine serum (FBS) (Invitrion) and cultured for a maximum of 9 days to reach blastocyst stage, with medium change every other day.

ESC derivation
--------------

Blastocysts generated by PG activation and ICSI were selected to establish ESC lines as described^[@bib15]^. Zona pellucidae of PG blastocysts were removed by brief exposure (45-60 s) to 0.5% pronase in ESC-derivation medium. For immunosurgical isolation of ICMs, zona-free blastocysts were exposed to rabbit anti-rhesus spleen serum (Axell Labs, Westbury, NY, USA) (1:5) for 30 min at 37 °C. After extensive washing in ESC derivation medium, embryos were incubated in guinea pig complement (Sigma) (1:5) for an additional 30 min at 37 °C. Partially lysed trophectodermal cells were mechanically dispersed by gentle pipetting with a small-bore pipette followed by the rinse of ICM three times with ESC-derivation medium. Each isolated ICM was transferred into one well of the four-well dishes (Nunc) seeded with mitotically inactivated HFF feeders^[@bib16]^ in ESC-derivation medium, composed of F-12 medium (Invitrogen) supplemented with 1% nonessential amino acids (Invitrogen), 2 mM L-glutamine (Invitrogen), 0.1 mM β-mercaptoethanol, 50 units/ml penicillin, 50 μg/ml streptomycin (Invitrogen), 20% KO-SR replacement, 40 ng/ml bFGF (Invitrogen), 2 mM Thiazovivin (Selleck) and 10 mM Y-27632 (Selleck). After 10-14 days in culture, outgrowths were manually dissociated into small-cell clumps with a microscalpel and transferred to a four-well plate with a fresh feeder layer in fresh medium. After the first several passages, colonies with ESC-like morphology were selected for further propagation, characterization and low-temperature storage. Established ESCs were expanded in ESC culture medium, which is similar to ESC-derivation medium, with modification of supplementation with 10 ng/ml bFGF. The culture medium was changed daily, and ESC colonies were split every 5-7 days manually or disaggregated by Accutase (Millipore).

Karyotype analysis
------------------

ESCs were incubated with 400 ng/ml demecolcine (Sigma) for 4 h. After being scraped off the ESCs were resuspended in 0.075 M KCl at 37 °C for 30 min. Hypotonic solution-treated cells were fixed in methanol:acetic acid (3:1 in volume) for 30 min and dropped onto precleaned slides. Chromosome spreads were Giemsa-banded and photographed. Karyotypes were assessed by normal G-banding procedure, and a normal karyotype would show normal chromosome numbers and G-banding patterns in the spreads examined. More than 10 M-phase spreads were analyzed.

Immunostaining
--------------

Cells on glass coverslips were fixed in PBS supplemented with 4% paraformaldehyde for 15 min at room temperature (RT). The cells were then permeabilized using 0.2% Triton X-100 in PBS for 15 min at RT. The cells were blocked for 30 min in 1% BSA in PBS. All primary antibodies against Oct4 (1:100) (sc-5279, Santa Cruz), Nanog (1:100) (RCAB002P-F, Reprocell), SSEA-1 (1:100) (mab4301, Millipore), SSEA-4, TRA-1-60, TRA-1-81 and Sox2 (1:100) (ab5603, Millipore) were diluted in the same blocking buffer and incubated with the samples overnight at 4 °C. The cells were treated with a fluorescently coupled secondary antibody and then incubated for 1 h at RT. The nuclei were stained with Hoechst 33342 (Sigma) for 10 min at RT.

FACS
----

To sort haploid cells, ESCs were disaggregated by Accutase, washed by Dulbecco\'s Phosphate-Buffered Saline (GIBCO) and then incubated with 15 mg/ml Hoechst 33342 in a 37 °C water bath. Subsequently, the haploid 1n peak was purified using BD FACS AriaII for further culturing. For analysis, after fixation in 4% paraformaldehyde, cells were digested by 20 mg/ml RNase A and stained with 50 mg/ml propidium iodide (PI). Analytic flow profiles were recorded by BD LSRII SORP.

Quantitative reverse transcription PCR
--------------------------------------

Total RNA was isolated from the cells using Trizol reagent (Invitrogen). One microgram of total RNA was reverse transcribed using a First Strand cDNA Synthesis kit (TOYOBO). Real-time quantitative PCR reactions were set up in triplicate using the SYBR Green Realtime PCR Master Mix (TOYOBO) and run on a Bio-Rad CFX96. All of the gene expression levels were normalized to the internal standard gene, *GADPH*. Primer information is presented in [Supplementary information, Table S5](#sup1){ref-type="supplementary-material"}.

Bisulphite sequencing
---------------------

To obtain monkey sperm and tissue genomic DNA, samples were pretreated with tissue digest buffer, supplemented with dithiothreitol and 1% SDS (for sperm only) for 3 h, followed by proteinase K lysis and phenol-chloroform extraction. For DNA methylation analysis in ESCs and fibroblast, bisulphite conversion was performed in agarose beads as described^[@bib48]^. The PCR products were cloned into pMD19-T vectors (Takara), and individual clones were sequenced by Invitrogen, Shanghai, China. Bisulphite primer information is presented in [Supplementary information, Table S5](#sup1){ref-type="supplementary-material"}.

Microarray analysis
-------------------

RNAs from three monkey diploid ESC lines (MES1, MES2 and MES3), two haploid ESC lines (MPH1 passages7, 8, 9 and 11, and MPH2 passage 4) and duplicates of MFs (MF1 and MF2) from female individuals were extracted using TRIZOL Reagent (Life Technologies) and checked for a RIN number to inspect RNA integrity by an Agilent Bioanalyzer 2100 (Agilent Technologies). Qualified total RNA was further purified by RNeasy micro kit (QIAGEN) and RNase-Free DNase Set (QIAGEN). Affymetrix Rhesus Macaque Gene Chip was used for gene expression analysis. RNA amplification, labeling, array hybridization and data acquisition were performed at the Shanghai Biochip Company following the manufacturer\'s instructions. The data were analyzed using Genespring GX software (Agilent Technologies). The relatedness of transcription profiles was determined by calculating the Pearson\'s correlation coefficient (*r*).

Comparative genomic hybridization
---------------------------------

DNA samples (MPH1 passages 11 and 20, MPH2 passage 5 and adipose tissue from a female monkey) for CGH experiments were extracted using DNeasy Blood & Tissue Kit (QIAGEN). The DNA was purified by using 1% agarose gel electrophoresis, and quality of DNA was checked using NanoDrop (ThermoFisher). Agilent Acgh G3 Rhesus Macaque 4×180k was used for CGH analyis. Genomic DNA digestion, sample labeling, array hybridization and data acquisition were performed at the Shanghai Biochip Company following the manufacturer\'s instructions.

Embryoid body formation
-----------------------

Monkey PG-haESCs were digested into small clumps by using 5 mg/ml collagenase IV (GIBCO), and suspension culture was performed with these small clumps in low-attachment dishes for 9 days. Then, formed EBs were replated onto matrigel-coated glass slides for additional 3 days for immunofluorescence staining. The culture medium was DMEM/F12 (GIBCO) with 20% FBS (Hyclone), 2 mM L-glutamine (Invitrogen), 1% nonessential amino acids (Invitrogen), 0.1 mM β-mercaptoethanol (Sigma), 100 U/ml penicillin and 100 μg/ml streptomycin (Invitrogen).

Teratoma formation
------------------

For teratoma induction, we harvested 2 × 10^7^ cells of each PG-haESC line in 400 μl F12/DMEM (30% matrigel). We injected 200 μl of the cell suspension (1 × 10^7^ cells) intramuscularly into NOD SCID mice with matrigel. After 8-12 weeks, teratomas were harvested. Sections were stained with hematoxylin and eosin.

Growth curve detection
----------------------

Cells were plated onto 96-well plate in a density of 500 cells per well. Ten microlitre 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) (Sangon Biotech) with a concentration of 5 mg/ml was added into each well on day 1, 3, 5, 7, 9, 11 and 12 ys. MTT assays were performed as reported previously^[@bib30]^.

PB transfection and insertion site characterization
---------------------------------------------------

*PB* (*PGK-neo*) and *ACT-PBase* were co-transfected into cells by lipofectamine (Invitrogen). Transfectants were cultured and screened by using G418 with a concentration of 250 μg/ml. To construct *PB-PGK-neo-f2*, the *PGK-neo* gene, a 1.7-kb *Spe*I-*Mun*I fragment from pBigT was cloned into *PB* (*ACT-RFP*)DS to make PB-PGK-neo-f1, and thena 300-bp fragment from pBigT being cloned into *Spe*I sites of PB-PGK-neo-f1. For characterization of the insertion sites of *PB* element, genomic DNA was digested with *Hae*III in 37 °C and the products were self-ligated. Then, ligated DNA was used as a template for PCR detection with primers PB-RF and PB-RR to detect the insertion sites as reported previously^[@bib34]^.

Statistical analysis
--------------------

Differences of gene expression levels between groups were analyzed by means of Student\'s *t*-test. All statistical analyses were done by SPSS software 13.0.

Accession numbers
-----------------

Gene expression and CGH data sets can be accessed as the GEO reference series GSE43980 (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=rbsffoccawogyxw&acc=GSE43980>). This series includes the GSE43978 (mRNA expression datafrom monkey PG-haESC, diploid ESC and fibroblast) and the GSE43979 (CGH analysis of monkey PG-haESCs) data sets.
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![Derivation of monkey PG-haESCs. **(A)** Representative images of different stages of monkey ESC line derivation. PB, polar body; PN, pronucleus; ICM, inner cell mass. Scale bar, 100 μm (top, middle panel and bottom left) and 500 μm (bottom right). **(B)** Establishment of PG-haESC line (represented by MPH1) after three times of FACS enrichment for haploid cells. Right is FACS data of diploid control ESCs for comparison. D62, 62 days after the ICM was plated for ESC formation. **(C)** Karyotype of MPH1 (passage 7) and MPH2 (passage 5) showing the normal haploid complement of 21 chromosomes (20 + X). **(D)** CGH analysis of PG-haESCs (MPH1, passage 11) and female monkey adipose cells. Upper panel, MPH1 (p11) vs adipose cells. Lower panel, adipose cells vs adipose cells. No major genomic alterations (amplifications or losses) were detected in monkey PG-haESCs.](cr201393f1){#fig1}

![Pluripotency of monkey PG-haESCs. **(A)** Expression of primate ESC markers in monkey PG-haESCs, including *Nanog*, *Oct4*, *SSEA4*, *TRA-1-60* and *TRA-1-81*. Mouse-specific ESC marker, such as *SSEA1*, was not detected. Shown are the representative immunostaining images of monkey PG-haESC colonies. Scale bar, 100 μm. **(B)** Gene expression profiles of PG-haESCs. Scatter plots showing high correlation in gene expression between PG-haESCs and ICSI-derived diploid ESCs. Diploid ESCs, three replicates (MES1, MES2 and MES3). Haploid, five replicates (MPH1, passages 7, 8, 9 and 11; MPH2, passage 4). Fibroblasts, monkey somatic fibroblasts (MF1 and MF2 from female individuals, two replicates). **(C)** Expression of markers of various cells from different germ layers in EBs formed from PG-haESCs, including *TUJ1* (ectoderm), *ACTININ* (mesoderm) and *SOX17* (endoderm). Scale bar, 50 μm. **(D)** Histochemical analysis of teratomas from PG-haESCs. Representative images indicated the existence of tissues from all three embryonic germ layers, such as neural epithelial (ectoderm), cartilage (mesoderm) and intestinal epithelium (endoderm). Scale bar, 100 μm.](cr201393f2){#fig2}

![Cellular origin of MPH1 and MPH2. **(A)** Representative images of STR locus (D6S501) of MPH1 and MPH2 and their egg donors (no. 183 and no. 118). **(B)** Representative images of SNP locus (rs5436199) of MPH1 and MPH2 and their egg donor monkeys (no. 183 and no. 118). **(C)** Expression of the imprinted genes measured by qPCR. The expression levels in PG-haESCs were relative to those in diploid ESCs, which were set to 1. ^\*^0.01 \< *P* \< 0.05; ^\*\*^0.001 \< *P* \< 0.01. **(D)** Methylation analysis of *SNRPN* and *H19* in monkey skin, sperm, diploid ESCs (MES2, passage 4 for *SNRPN*, and passage 10 for *H19*) and PG-haESCs (MPH1, passage 5 for *H19* and passage 7 for *SNRPN*; MPH2, passage 9 for *H19* and passage 8 for *SNRPN*). Open and filled circles represent unmethylated and methylated CpG sites, respectively.](cr201393f3){#fig3}

![Haploidy in monkey PG-haESCs. **(A)** Maintenance of haploidy in MPH1 and MPH2. MPH1^a^ and MPH2^a^ represented subclones formed after replating haploid cells enriched via FACS from MPH1 and MPH2, respectively. **(B)** Growth curves of monkey PG-haESCs (MPH1 and MPH2), monkey diploid ESCs (MES1 and MES2) and mouse haESCs. MTT assay for monitoring cell growth was performed for three times. ^\*\*^*P* \< 0.01. **(C)** Flow cytometry analysis of DNA content of cells isolated from two teratomas. D70, 70 days after injection of PG-haESCs into NOD SCID mouse. **(D)** Expression of the differentiated genes measured by qPCR. The expression levels in diploid cells isolated from teratomas were relative to those in PG-haESCs, which were set to 1.](cr201393f4){#fig4}

![Genetic manipulation in monkey PG-haESCs. **(A)** Generation of transgenic PG-haESCs via drug selection. After co-transfection of donor *PB (Act-RFP)* carrying a neomycin-resistant gene (*neo^r^*) and the helper plasmid *ACT-PBase* into PG-haESCs and antibiotic (G418) selection, almost all neomycin-resistant cells were RFP positive (left). G418-resistant cells were replated and RFP-positive clones were picked for expansion, leading to 12 haploid ESC lines (right). Scale bars, 200 μm. **(B)** Diagram of PB insertional mutagenesis screening in monkey PG-haESCs. After introducing both *PB (PGK-neo)* and *ACT-PBase* into PG-haESCs and G418 selection, survived clones were picked for expansion. Clones with haploid population were selected for further analyses. **(C)** Four mutated cell lines were established from G418-resistant clones through multiple passages and FACS enrichment for haploid cells. **(D)** Confirmation of three genes (*PRKD1*, *NIF3L1* and *LIPC*) mutated in four clones, respectively. Normal PG-haESCs were used as control (lane one). **(E)** Expression of the *NIF3L1* gene measured by qPCR. The expression levels in mutated PG-haESCs were relative to those in ha-ESCs, which were set to 1. ^\*\*^*P* \< 0.01.](cr201393f5){#fig5}

###### Derivation of monkey ESCs from parthenogenetic and ICSI-derived blastocysts

  Treatment       Monkey number    No. of oocytes   No. of two-cell embryos   No. of compacted morulae   No. of blastocysts   No. of outgrowths   No. of established ESC lines   No. of PG-haESC lines
  --------------- --------------- ---------------- ------------------------- -------------------------- -------------------- ------------------- ------------------------------ -----------------------
  Ionomycin/CHX   128                    5                     3                         3                       1                    0                        0                           0
  Ionomycin/CHX   183                    6                     6                         6                       3                    1                        1                           1
  Ionomycin/CHX   147                    5                     5                         5                       0                    0                        0                           0
  Ionomycin/CHX   212                    5                     1                         0                       0                    0                        0                           0
  Ionomycin/CHX   97                     5                     5                         5                       2                    0                        0                           0
  Ionomycin/CHX   154 and 164            23                   23                         22                      11                   5                        4                           0
  Ionomycin/CHX   152                    14                   11                         11                      5                    0                        0                           0
  Ionomycin/CHX   95                     7                     4                         4                       0                    0                        0                           0
  Ionomycin/CHX   69                     7                     7                         2                       0                    0                        0                           0
  Ionomycin/CHX   26                     15                   15                         15                      9                    4                        0                           0
  Ionomycin/CHX   45                     5                     4                         4                       2                    0                        0                           0
  Ionomycin/CHX   102                    9                     9                         9                       4                    0                        0                           0
  Ionomycin/CHX   27                     3                     3                         3                       2                    0                        0                           0
  Ionomycin/CHX   161                    30                   30                         30                      11                   5                        0                           0
  Ionomycin/CHX   191                    1                     1                         1                       1                    0                        0                           0
  Ionomycin/CHX   197                    1                     1                         1                       0                    0                        0                           0
  Ionomycin/CHX   115                    6                     6                         6                       4                    0                        0                           0
  Ionomycin/CHX   227                    4                     4                         2                       1                    1                        1                           0
  Ionomycin/CHX   118                    28                   27                         24                      13                   5                        4                           1
  Ionomycin/CHX   14                     1                     1                         1                       0                    0                        0                           0
  Ionomycin/CHX   211                    1                     1                         1                       1                    0                        0                           0
  Subtotal                              181                   167                       155                      70                  21                        10                          2
  ICSI            5                      15                   15                         7                       4                    2                        1                           /
  ICSI            87                     3                     3                         3                       1                    1                        0                           /
  ICSI            183                    10                    8                         4                       2                    1                        0                           /
  ICSI            195                    9                     4                         3                       2                    1                        0                           /
  ICSI            207                    7                     6                         4                       4                    3                        0                           /
  ICSI            50                     20                   13                         10                      10                  10                        3                           /
  Subtotal                               64                   49                         31                      23                  18                        4                           /

Abbreviations: CHX, cycloheximide; ESC, embryonic stem cell; haESC, haploid embryonic stem cell; ICSI, intracytoplasmic sperm injection.

[^1]: These three authors contributed equally to this work.
